Table 1. Demographic and Clinical Characteristics of the Study Population.
| Characteristic | Participants, No. (%) | |||
|---|---|---|---|---|
| CCSS (n = 20 367)a | DCOG-LATER (n = 5741) | SJLIFE (n = 2315) | Total (N = 28 423) | |
| Female sex | 9570 (46.8) | 2541 (44.3) | 1104 (47.7) | 13 215 (46.4) |
| Age at diagnosis, median (range), y | 6.3 (0.0-21.0) | 5.5 (0.0-17.9) | 6.3 (0.0-22.7) | 6.1 (0.0-22.7) |
| Primary childhood cancer diagnosis | ||||
| Leukemia | 5881 (37.3) | 2012 (35.0) | 847 (36.6) | 8740 (36.3) |
| Lymphoma | 4097 (18.0) | 1004 (17.5) | 376 (16.2) | 5477 (17.7) |
| Brain tumor | 3820 (16.7) | 731 (12.7) | 292 (12.6) | 4843 (15.7) |
| Neuroblastoma | 1600 (7.0) | 302 (5.3) | 121 (5.2) | 2023 (6.6) |
| Kidney tumor | 1814 (8.0) | 566 (9.9) | 167 (7.2) | 2547 (8.3) |
| Soft-tissue sarcoma | 1451 (6.4) | 413 (7.2) | 142 (6.1) | 2006 (6.5) |
| Bone tumor | 1704 (7.5) | 326 (5.7) | 121 (5.3) | 2151 (7.0) |
| Other malignant neoplasm | 0 | 387 (6.7) | 249(10.8) | 636 (2.1) |
| Treatment exposures | ||||
| Doxorubicin | 6686 (35.4) | 1805 (31.8) | 839 (36.3) | 9330 (34.8) |
| Dose, median (IQR), mg/m2 | 198 (114-331) | 150 (100-300) | 185 (151-278) | 181 (119-320) |
| Daunorubicin | 2697 (16.7) | 1084 (19.0) | 652 (28.2) | 4433 (18.0) |
| Dose, median (IQR), mg/m2 | 108 (98-265) | 126 (120-175) | 100 (50-105) | 120 (99-208) |
| Epirubicin | 1 (0.1) | 340 (5.9) | 1 (0.1) | 342 (1.1) |
| Dose, median (IQR), mg/m2 | 175 | 300 (240-400) | 270 | 300 (240-400) |
| Idarubicin | 153 (1.1) | 61 (1.1) | 27 (1.2) | 241 (1.1) |
| Dose, median (IQR), mg/m2 | 30 (20-41) | 36 (35-36) | 20 (11-36) | 36 (20-40) |
| Mitoxantrone | 99 (0.5) | 139 (2.4) | 27 (1.2) | 265 (0.9) |
| Dose, median (IQR), mg/m2 | 47 (32-80) | 40 (20-60) | 50 (36-51) | 40 (26-72) |
| Chest radiotherapy | 4896 (22.9) | 771 (13.4) | 573 (24.8) | 6240 (21.2) |
| Dose, median (IQR), Gy | 26 (15-37) | 24 (16-35) | 25 (15-30) | 25 (15-36) |
| Attained age, median (range), y | 27.1 (5.6-40.0) | 27.3 (5.1-40.0) | 31.6 (18.9-40.0) | 27.5 (5.1-40.0) |
| Cardiomyopathy casesb | 270 (1.4) | 106 (1.8) | 23 (1.0) | 399 (1.4) |
Abbreviations: CCSS, Childhood Cancer Survivor Study; DCOG-LATER, Dutch Children’s Oncology Group LATER cohort; IQR, interquartile range; SJLIFE, St Jude Lifetime Cohort Study.
a
Percentages may not match numbers because percentages reflect weighting used in the CCSS for patients with acute lymphoblastic leukemia; reported median values and IQR also reflect weighting.
b
Defined using Common Terminology Criteria for Adverse Events, grade 3 or higher, requiring medical treatment, life-threatening, or fatal.